Introduction
Human tumours propagated as xenografts in immune-suppressed mice are being used increasingly to study clinical chemotherapy reponse in human cancer (Phillips & Gazet 1970 , Cobb & Mitchley 1974 , Kopper & Steel 1975 . Some of these studies are based on measurements of tumour growth delay in the treated xenograft-bearing animal; more recently, the development of soft agar colony-forming assays for clonogenic human tumour cells obtained from xenografts has allowed more specific information on tumour cell radiosensitivity and chemosensitivity to be determined . Here, studies on the chemosensitivity of clonogenic tumour cells from a human pancreatic carcinoma xenograft, using an agar diffusion chamber assay, are described and their possible clinical significance discussed.
Methods
The human tumour xenograft used in these studies was obtained at laparotomy from a 34year-old man with widespread peritoneal metastases arising from a poorly differentiated tumour apparently originating in the pancreas. Details of its implantation into thymectomized, whole body irradiated, marrow reconstituted CBA/lac mice have already been described (Pickard et al. 1975) .
Single cell suspensions of this tumour were obtained for the diffusion chamber colonyforming assay used here by fine chopping using a cross-scalpel technique, followed by incubation in collagenase and 1: 100 trypsin. Tumour cell suspensions in Ham's median, fetal calf serum and 0.3% agar were grown in diffusion chambers implanted into the peritoneal cavity of C57BL mice pretreated with whole body irradiation; colonies of 50 cells or more were counted 21 days later. This technique has already been described in detail .
The diffusion chamber assay was used to measure tumour cell chemosensitivity in two ways. In the first, sensitivity was assayed in vivo by injecting the tumour-bearing mouse with the appropriate drug and dissecting out the tumour for assay 18 hours later (Figure l A). In the second technique, which I have termed in mure, a cell suspension of an untreated tumour was loaded into diffusion chambers for implantation, and the chamber-bearing mouse treated with drug; 18 hours later the chamber was transplanted into a second mouse ( Figure IB ). The advantage of the in vivo technique was that tumour cells in situ were exposed to drugs under physiological conditions, albeit murine. Compared with this, the in mure technique was obviously highly unphysiological. Nevertheless, the latter has the advantage that it can be adapted to study tumour cells obtained directly from a patient, bypassing the xenograft system. Furthermore, the in mure technique has already been used to study the chemosensitivity of cIonogenic human bone marrow cells (Gordon & Blackett 1976) , and therefore the relative chemosensitivities of human tumour and human bone marrow cells can be compared in the same system.
In all instances, clonogenic tumour cell survival after drug treatment was expressed as the fraction of colonies grown from single cell suspensions of treated tumours compared with those from untreated controls. Figure 2 shows cyclophosphamide dose-survival curves for pancreatic tumour cells treated both ill riro and in mure; a similar dose-survival curve previously obtained for human bone marrow cells exposed to cyclophosphamide in mure is superimposed (Gordon & Blackett 19?6) . Cells treated in vivo were extremely insensitive to cyclophosphamide with less than one log cell kill even at the maximum tolerated dose to the mouse: the predicted 0 10 (the drug dose required to achieve one log cell kill) was 456 mg/kg. Tumour cells treated in mure were more sensitive to cyclophosphamide than in vivo (0 10 169 rug/kg), but much less sensitive than human bone marrow cells similarly treated (0 10 37 mg/kg), Figure 3 shows the effect on pancreatic tumour cell survival of in vivo treatment with murine L0 10 doses of 5 cytotoxic drugs. Of these only methyl-CCNU achieved even one log cell kill, and the surviving fraction for each agent was as follows: adriamycin (IS mg/kg), 0.51; 5fluorouracil (250 mg/kg), 0.63; methotrexate (200 mg/kg), 0.40; methyl-CCNU (30 mg/kg), 0.08; and vinblastine (3 mg/kg), 0.49.
Discussion
The in vivo cyclophosphamide experiments demonstrate the striking insensitivity to this drug of the pancreatic tumour cell studied here; by comparison, the dose required to achieve one log kill is about 4 times as great as that required even for the EMT6 tumour, one of the most cyclophosphamide-resistant experimental animal tumours (Steel 1977) . The failure of 4 other drugs to achieve even one log kill at high dosage was equally striking, and these observations correlate well with the clinical experience that single agent chemotherapy of whatever type is rarely effective in the treatment of pancreatic carcinoma (Moertel 1973) . Cyclophosphamide sensitivity in mure is greater than in vivo in this system, and this may be based on inadequate tumour perfusion with drug when treated in vivo (Rowe-Jones 1968). Consequently, the in mure technique would measure the intrinsic chemosensitivity of clonogenic tumour cells, whereas the in vivo technique would reflect the modification of intrinsic chemosensitivity by extrinsic factors, such as inadequate perfusion, under physiological conditions. This observation is important in that similar studies on tumour cells taken direct from the patient using the in mure technique might overestimate their sensitivity, at least to some cytotoxic drugs, under physiological conditions.
The increased sensitivity to cyclophosphamide of human marrow compared with human pancreatic tumour cells is of interest in that the reverse has usually been found in experimental animal tumour systems, murine marrow cells being much less sensitive to this drug than murine tumour cells (Bruce et at. 1966 , van Putten & Lelieveld 1970 . Again, these comparative chemosensitivity data on human cells are compatible with clinical experience which has demonstrated that cyclophosphamide even in doses high enough to cause marrow suppression rarely achieves a response in pancreatic carcinoma (Moertel 1973) .
Conclusion
These studies demonstrate that it is now feasible to measure the chemosensitivity of clonogenic human tumour cells in a way previously restricted to cells from experimental animal tumours. Further data are clearly required before the value of this type of information can be fully assessed. However, these preliminary results suggest that this type of system may be a more valid model than that provided by experimental animal tumours for the laboratory study of clinical response to chemotherapy.
A practical method for ensuring long-term venous access 1
Professor Peter Jacobs MRcpath FACP Jack Jacobson MB FRCS University of Cape Town Leukaemia Centre and Departments ofHaematoloqy, Clinical Science and Immunology, Groote Schuur Hospital, Observatory, Cape 7925, South Africa Reliable venous access is of critical importance in the management of the chronically ill and debilitated patient. It is also indispensable during the period when cytotoxic chemotherapy is infused for induction of remission in patients with acute leukaemia and following bone marrow transplantation, when the patients may depend upon intravenous therapy continuously for 6 weeks or more. In these circumstances, consideration must be given to the risks of introducing infection that follow repeated venepunctures in immunocomprised patients, while movement for nursing procedures and physiotherapy inevitably disturb the safety of a peripherallylocated venous line.
In an attempt to resolve these problems a technique was developed based on earlier studies in a rabbit model (Jacobs 1973 , Jacobs & Adriaenssens 1970 where an entirely subcutaneous plastic system had been implanted; the reservoir remained available for intermittent sampling and provided intravenous access over a 3-month period. The same method is equally applicable to man, but we have recently modified this because, following irradiation and bone marrow transplantation, continuous as opposed to intermittent venous access is mandatory.
